Treatment of angina pectoris with nifedipine.
作者信息
Idle J R, Sever P S
出版信息
Br Med J (Clin Res Ed). 1983 Jun 18;286(6382):1978-9. doi: 10.1136/bmj.286.6382.1978-e.
Abstract
摘要
相似文献
1
Treatment of angina pectoris with nifedipine.硝苯地平治疗心绞痛
Br Med J (Clin Res Ed). 1983 Jun 18;286(6382):1978-9. doi: 10.1136/bmj.286.6382.1978-e.
2
Nifedipine for angina pectoris.
Med Lett Drugs Ther. 1982 Apr 16;24(607):39-41.
3
[Angina pectoris; variations on the nifedipine theme].
Ned Tijdschr Geneeskd. 1980 Nov 8;124(45):1928-32.
4
Are propranolol and nifedipine synergistic in angina pectoris?普萘洛尔和硝苯地平在心绞痛治疗中具有协同作用吗？
Br J Clin Pharmacol. 1982 Feb;13(2):255-6. doi: 10.1111/j.1365-2125.1982.tb01375.x.
5
[The treatment of angina pectoris with nifedipine in a new administrative form].[硝苯地平新型剂型治疗心绞痛]
Med Welt. 1981 May 1;32(18):709-12.
6
Suppression of repeatedly occurring ventricular fibrillation with nifedipine in variant form of angina pectoris.
Br J Clin Pract Suppl. 1980;8:73-5.
7
Nifedipine (Adalat) for angina.硝苯地平（心痛定）用于治疗心绞痛。
Drug Ther Bull. 1979 Mar 16;17(6):22-4.
8
9
10
Factors influencing the treatment of chronic stable angina pectoris with nifedipine.硝苯地平治疗慢性稳定型心绞痛的影响因素。
Postgrad Med J. 1983;59 Suppl 2:25-9.
引用本文的文献
1
Protecting the poor metaboliser--from what?保护代谢缓慢者——免受什么影响？
Br J Clin Pharmacol. 1984 Apr;17(4):488-96. doi: 10.1111/j.1365-2125.1984.tb02380.x.
2
Variability of plasma drug concentrations: some observations.
Eur J Clin Pharmacol. 1983;25(4):569-70. doi: 10.1007/BF00542131.
3
Twelve hour (trough) plasma nifedipine concentrations during chronic treatment with nifedipine retard.硝苯地平缓释片长期治疗期间的12小时（谷值）血浆硝苯地平浓度。
Eur J Clin Pharmacol. 1987;32(4):347-9. doi: 10.1007/BF00543967.
4
Adverse drug reaction reporting and retrospective phenotyping for oxidation polymorphism.氧化多态性的药物不良反应报告及回顾性表型分析
Med Toxicol Adverse Drug Exp. 1988 May-Jun;3(3):241-7. doi: 10.1007/BF03259884.
本文引用的文献
1
Identification of nifedipine metabolites and their determination by gas chromatography.
Chem Pharm Bull (Tokyo). 1980 Jan;28(1):1-7. doi: 10.1248/cpb.28.1.
2
Genetically determined oxidation capacity and the disposition of debrisoquine.遗传决定的氧化能力与异喹胍的代谢
Br J Clin Pharmacol. 1983 Apr;15(4):443-50. doi: 10.1111/j.1365-2125.1983.tb01528.x.
3
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.患有哌克昔林神经病变患者的异喹胍氧化受损。
Br Med J (Clin Res Ed). 1982 Jan 30;284(6312):295-9. doi: 10.1136/bmj.284.6312.295.
4
Clinical pharmacokinetics of calcium channel antagonists.
J Cardiovasc Pharmacol. 1982;4 Suppl 3:S340-5.
5
Polymorphic hydroxylation of Debrisoquine in man.人对异喹胍的多态性羟基化作用。
Lancet. 1977 Sep 17;2(8038):584-6. doi: 10.1016/s0140-6736(77)91430-1.
Zotero 插件